Turn Biotechnologies aims to change paradigm in skin rejuvenation with Epigenetic Reprogramming of Aging treatment.

Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, has released preliminary data that show its therapies can rejuvenate skin cells more effectively and safely than existing treatments.

Longevity.Technology: Turn Bio’s ERA™ (Epigenetic Reprogramming of Aging) treatment, is precisely transported using Turn Bio’s proprietary eTurna™ – a lipid-based delivery platform; the treatment reversed the hallmarks of aging in human skin – something which, the company claims, has never before been achieved. Results show that the treatment simultaneously increased fibroblasts and collagen VII to restore the production of collagen and elastin, and reduced inflammation markers, oxidative stress, senescence and MMPs (proteins responsible for skin degradation) versus those untreated.

Preclinical data were presented to dermatologists and industry KOLs attending four global conferences in the past five weeks: Global Aesthetics Conference in Miami, Cosmetic Surgery Forum in Nashville, Tennessee, Beauty Through Science in New York City and The Longevity Summit in San Francisco, California.

“The data suggest we may be close to redefining the care dermatologists can provide their patients,” said Jill Waibel, a board-certified dermatologist and respected regenerative medicine researcher who presented findings at the Global Aesthetics Conference.

“The potential to improve the quality of patients’ skin – its elasticity and its ability to heal – could change the future of regenerative medicine.”

Read our Advanced Aesthetics report absolutely free and discover how the root causes of skin and hair aging are being targeted and tackled.

Hema Sundaram, a board-certified dermatologist and noted researcher in regenerative medicine and cell science, presented the data at Cosmetic Surgery Forum.

“This early research suggests that ERA could significantly improve the balance between key biomarkers of cell aging and cell youthfulness,” she said. “From an evidence-based perspective, this carries more weight as a rejuvenation strategy than efforts to improve a single biomarker. Research of this type may open the door to a new paradigm of dermatologic care.”

Data were also presented during sessions of the Beauty Through Science conference and the Longevity Summit.

“We believe this promises to be a game-changer for dermatologists, plastic surgeons and their patients,” said Turn Bio CEO Anja Krammer. “The true breakthrough of combining our mRNA-based ERA therapy with our eTurna lipid delivery system, for the first time shows reversal from the effects of aging and offers an ability to improve the overall quality of the skin.”

Turn Bio has also committed to releasing additional data during a January webinar, with details being announced in coming weeks.